Journal of Thrombosis and Thrombolysis

, Volume 38, Issue 1, pp 121–123 | Cite as

Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation

  • Christophe Vandenbriele
  • Thomas Vanassche
  • Marijke Peetermans
  • Peter Verhamme
  • Kathelijne Peerlinck
Article
First Online:

Abstract

The localized activation of coagulation in vascular malformations can lead to a consumptive coagulopathy characterized by elevated D-dimers and a consumption of fibrinogen and platelets, eventually giving rise to a bleeding tendency. By reducing coagulation activation, anticoagulant treatment with heparin is able to limit this haemostatic dysregulation and the associated bleeding diathesis. Here, we present a case of a consumptive coagulopathy due to a large venous malformation with a sustained correction of the fibrinogen depletion and associated bleeding tendency both with subcutaneous enoxaparin and with the oral factor Xa inhibitor rivaroxaban.

Keywords

Enoxaparin Rivaroxaban Disseminate Intravascular Coagulation Vascular Malformation Fibrinogen Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Hermans C, Dessomme B, Lambert C, Deneys V (2006) Venous malformations and coagulopathy. Ann Chir Plast Esthet 51(4–5):388–393. doi: 10.1016/j.anplas.2006.07.009 PubMedCrossRefGoogle Scholar
  2. 2.
    Martin LK, Russell S, Wargon O (2009) Chronic localized intravascular coagulation complicating multifocal venous malformations. Aus J Dermatol 50(4):276–280. doi: 10.1111/j.1440-0960.2009.00558.x CrossRefGoogle Scholar
  3. 3.
    Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, Pocock B, Lequerrec A, Labbe D, Barrellier MT, Vanwijck R, Vikkula M, Boon LM (2008) Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 144(7):873–877. doi: 10.1001/archderm.144.7.873 PubMedCrossRefGoogle Scholar
  4. 4.
    Mazoyer E, Enjolras O, Laurian C, Houdart E, Drouet L (2002) Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach–Merritt syndrome. Clin Lab Haematol 24(4):243–251PubMedCrossRefGoogle Scholar
  5. 5.
    Mazoyer E, Enjolras O, Bisdorff A, Perdu J, Wassef M, Drouet L (2008) Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 144(7):861–867. doi: 10.1001/archderm.144.7.861 PubMedCrossRefGoogle Scholar
  6. 6.
    Enjolras O, Ciabrini D, Mazoyer E, Laurian C, Herbreteau D (1997) Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. J Am Acad Dermatol 36(2 Pt 1):219–225PubMedCrossRefGoogle Scholar
  7. 7.
    Scola M, Brophy M, Fiore L (2001) Localized consumptive coagulopathy. Circulation 104(1):120–121PubMedCrossRefGoogle Scholar
  8. 8.
    Garzon MC, Huang JT, Enjolras O, Frieden IJ (2007) Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol 56(4):541–564. doi: 10.1016/j.jaad.2006.05.066 PubMedCrossRefGoogle Scholar
  9. 9.
    Bick RL (1981) Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci 370:851–854PubMedCrossRefGoogle Scholar
  10. 10.
    Verstraete M, Amery A, Vermylen C, Robyn G (1963) Heparin treatment of bleeding. Lancet 1(7278):446PubMedCrossRefGoogle Scholar
  11. 11.
    Feinstein DI (1982) Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 60(2):284–287PubMedGoogle Scholar
  12. 12.
    Jelenska MM, Szmidt J, Bojakowski K, Grzela T, Palester-Chlebowczyk M (2004) Compensated activation of coagulation in patients with abdominal aortic aneurysm: effects of heparin treatment prior to elective surgery. Thromb Haemost 92(5):997–1002. doi: 10.1267/THRO04050997 PubMedGoogle Scholar
  13. 13.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 365(10):883–891. doi: 10.1056/NEJMoa1009638 PubMedCrossRefGoogle Scholar
  14. 14.
    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 363(26):2499–2510. doi: 10.1056/NEJMoa1007903 PubMedCrossRefGoogle Scholar
  15. 15.
    EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med 366(14):1287–1297. doi: 10.1056/NEJMoa1113572 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Christophe Vandenbriele
    • 1
  • Thomas Vanassche
    • 1
  • Marijke Peetermans
    • 1
  • Peter Verhamme
    • 1
  • Kathelijne Peerlinck
    • 1
  1. 1.Vascular Medicine and Haemostasis, Department of Cardiovascular DiseasesUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations